Program
golidocitinib
Also written as “AZD4205”, “GW5282 combined with Golidocitinib” and “DZD9008+AZD4205”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, led by Dizal Pharmaceuticals.
Furthest: phase 3, since Nov 14, 202510 company-led studies, 2 open or runningNext primary completion: Nov 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dizal Pharmaceuticals | 102 open or running | phase 3since Nov 14, 2025 | Jan 25, 2018 | Nov 30, 2027phase 3 · NCT07234162 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03450330 · 10 enrolled · Australia
- Oct 28, 2018Phase 1 study in Healthy VolunteersNCT03728023 · 66 enrolled · United States
- Sep 18, 2019Phase 2 study in RecurrenceNCT04105010 · 171 enrolled · United States, Australia, China and more
- Jan 3, 2020Phase 1 study in Healthy VolunteersNCT04225208 · 8 enrolled · United States
- Aug 2, 2022Phase 1 study in Healthy SubjectsNCT05486949 · 32 enrolled · United States
- Feb 7, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06295432 · 30 enrolled · China
- Jul 15, 20242 phase 2 studies in Lymphoma, T-Cell, PeripheralNCT06511895, NCT06511869
- Nov 14, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralNCT07234162 · 218 planned · China, Taiwan, Thailand
- Mar 16, 2026Phase 2 study in Lymphoma, T-CellNCT07496229 · 220 planned · China
Ahead
- Nov 30, 2027Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralNCT07234162
- Sep 2029Primary completion: phase 2 study in Lymphoma, T-CellNCT07496229
TargetBeta
JAK1 →read by rule
“An orally available inhibitor of Janus-associated kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule
Other programs on JAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| baricitinibrule | Eli Lilly | phase 4 | 59 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| abrocitinibrule | Pfizer | phase 3 | 30 |
| ivarmacitinibrule | Jiangsu HengRui Medicine | phase 3 | 25 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| momelotinibrule | GlaxoSmithKline | phase 3 | 17 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07496229Lymphoma, T-Cell · China | 2 | Recruiting | Sep 2029 | 220 |
| NCT07234162Lymphoma, T-Cell, Peripheral · China, Taiwan, Thailand | 3 | Recruiting | Nov 30, 2027 | 218 |
| NCT06511895Lymphoma, T-Cell, Peripheral · China | 2 | Completed | Oct 17, 2025 | 57 |
| NCT06511869Lymphoma, T-Cell, Peripheral · China | 2 | Completed | Mar 31, 2025 | 48 |
| NCT06295432Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jun 8, 2026 | 30 |
| NCT05486949Healthy Subjects · United States | 1 | Completed | Oct 8, 2022 | 32 |
| NCT04225208Healthy Volunteers · United States | 1 | Completed | Mar 2, 2020 | 8 |
| NCT04105010Recurrence · United States, Australia, China and more | 2 | Completed | Oct 12, 2023 | 171 |
| NCT03728023Healthy Volunteers · United States | 1 | Completed | Aug 20, 2019 | 66 |
| NCT03450330Carcinoma, Non-Small-Cell Lung · Australia | 2 | Completed | Sep 3, 2019 | 10 |
How it is read
Names in the registry
- “AZD4205”, 4 entries
- “GW5282 combined with Golidocitinib”, 3 entries
- “DZD9008+AZD4205”, 1 entry
- “Golidocitinib”, 1 entry
- “golidocitinib”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.